Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation (University of Alberta)
- Development stage
- Unknown
- Lead developer
- University of Alberta
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbiota transplantation (FMT) developed by the University of Alberta is an investigational therapy for obesity and metabolic syndrome. This therapy involves the transfer of gut microbes from lean, healthy donors to individuals with these conditions. The rationale is based on observations that the gut microbial composition differs between lean and obese individuals, and that altering the microbiome can impact metabolic health. [4, 6] The treatment is administered orally in a pill form and is studied in conjunction with dietary fiber supplementation. The fiber is intended to help sustain the beneficial microbial changes introduced by the transplant. [4] A Phase 2 clinical trial (NCT03477916) is evaluating the effects of this combination therapy on insulin sensitivity, weight, quality of life, and other metabolic parameters. [4]
- Other names
- fecal microbiota transplantation-University of Alberta-obesity-metabolic syndromeFecal Microbial Transplantation
Beyond the preview
Go deeper on fecal microbiota transplantation (University of Alberta).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation (University of Alberta).